Paul W. et al. indicated that the updated Lung-molGPA was associated with improved prognosis by incorporating the effect of EGFR and anaplastic lymphoma kinase (ALK) gene alterations on survival in NSCLC patients with BMs, comparison with Oncology Group Recursive Partitioning Analysis (RTOG RPA) and the original Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.